Miscellaneous

Phase Forward Delivers Strong 4Q, 2007

Monday, February 4, 2008 11:13 AM

Waltham, Mass.-based eClinical company Phase Forward reported strong fourth quarter and full 2007 annual results on Jan. 31. Revenues for the full year 2007 were $134.3 million, a 26% increase from $106.6 million in the previous year. More than 70%, or $96.9 million, of its total revenue stemmed from its electronic data capture product (EDC) product InForm.

More... »

CWWeekly January 28th 2008 Issue

Friday, February 1, 2008 11:09 AM

Top News   

More... »

Clinical Data, Affymetrix in Marketing Deal

Wednesday, January 30, 2008 12:26 PM

Newton, Mass.-based analytical services company Clinical Data signed a service and marketing agreement with Affymetrix, a diagnostic technology company based in Santa Clara, Calif. The agreement allows Clinical Data’s two subsidiaries, Cogenics and Epidauros Biotechnologies AG, to sell Affymetrix’s drug metabolizing enzymes and transporter (DMET) solution. DMET is a method for analyzing the genetics of drug metabolism. It allows sponsors to gain valuable data on pharmacokinetics compared to a patient’s genetic profile.

More... »

Parexel Builds Momentum, Boosts 2008 Outlook

Tuesday, January 29, 2008 09:47 AM

Parexel, a global contract research organization (CRO), continues on a nice roll with its shares up another 1.7% yesterday to $57—just off its 52-week high.

More... »

LabCorp to Acquire Tandem Labs

Monday, January 28, 2008 07:44 AM

Burlington, N.C.-based LabCorp has signed an agreement to acquire the bioanalytical services company Tandem Labs for an undisclosed amount. Tandem performs analytical lab work for drugs in all stages of development including discovery, preclinical, and clinical. Founded in 1981 as Northwest Toxicology Consultants, the company initially operated as a clinical toxicology reference laboratory.

More... »

CWWeekly January 22nd 2008 Issue

Friday, January 25, 2008 03:31 PM

Top News

More... »

Pharm-Olam Growth at Record Pace in 2007

Thursday, January 24, 2008 03:16 PM

Houston-based contract research organization (CRO) Pharm-Olam International reported record revenue growth in 2007, signing $100 million in new contracts signed in the 12 months.

More... »

Type I Diabetes Drug See Positive Results in Phase II

Thursday, January 24, 2008 10:11 AM

Diamyd Medical (formerly issued positive long-term results from a phase IIb trial of Diamyd, GAD-65), recombinant glutamic acid decarboxylase (GAD) delivered with alum for injection, for the treatment of type I diabetes. This randomized study enrolled seventy pediatric and adolescent subjects in Sweden.

More... »

Recent Industry Personnel Changes

Wednesday, January 23, 2008 09:46 AM

Contract Research

More... »

Kendle Looking to Grow Phase I Business

Monday, January 21, 2008 03:10 PM

Cincinnati-based CRO Kendle is expanding its phase I business with the appointment of Philip Davies, a 20-year industry veteran in early stage research, and made another key hire to grow its Asia-Pacific operations.

More... »